


**Product Name** : TRPM5 inhibitor NDNA  
**Cat. No.** : PC-20367  
**CAS No.** : 936628-69-2  
**Molecular Formula** : C<sub>21</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>  
**Molecular Weight** : 348.40  
**Target** : TRP Channel  
**Solubility** : 10 mM in DMSO



### Biological Activity

TRPM5 inhibitor NDNA is potent and selective **TRPM5** inhibitor, inhibits Ca<sup>2+</sup>-induced TRPM5 currents with IC<sub>50</sub> of 2.4 nM. NDNA binds to a region critical for channel gating, stabilizes the ion-conducting pore in an apo-like closed conformation. NDNA inhibits Ca<sup>2+</sup>-induced TRPM5 activation in a non-competitive manner.

NDNA enhances insulin release, GLP-1 release, and insulin sensitivity.

TPPO dose-dependently inhibited acidic pHe-induced MMP-9 production in B16-BL6 cells (IC<sub>50</sub>=41 μM), but did not reduce cell viability.

NDNA (10 mg/kg. s.c.) significantly reduced spontaneous lung metastasis, without affecting tumor growth, body weight, or CBG, in tumor bearing mice.

### References

Ruan Z, et al. *Nat Struct Mol Biol.* 2021 Jul;28(7):604-613.

Bryant R et al. Patent WO2008097504. Use of a trpm5 inhibitor to regulate insulin and glp-1 release.

Toyonobu Maeda, et al. *Oncotarget.* 2017 Sep 11;8(45):78312-78326.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com